Skip to main content
Novartis
language-selector-globe
Choose Location
  • International
  • Americas
  • Asia Pacific
  • Europe
  • Middle East & Africa
Global | English
Novartis Foundation | English
Argentina | Español
Brazil | Português
Canada | English
Canada | Français
Central America | Español
Colombia | Español
Mexico | Español
United States | English
Australia | English
Bangladesh | English
Hong Kong S.A.R. | 繁體中文
India | English
Indonesia | English
Japan | 日本語
Korea | 한국어
Mainland China | 中文
Malaysia | English
Pakistan | English
Philippines | English
Singapore | English
Taiwan | 繁體中文
Thailand | ภาษาไทย
Austria | Deutsch
Belgium | Français
Belgium | Nederlands
Bulgaria | Български
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hungary | Magyar
Ireland | English
Italy | Italiano
Latvia | Latvian
Lithuania | Lithuanian
Netherlands | Nederlands
Norway | Norsk
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Serbia | Srpski
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Türkiye | Türkçe
United Kingdom | English
Egypt | English
Israel | עברית
Saudi Arabia | العربية
South Africa | English
language-selector-globe
Choose Location
International Americas Asia Pacific Europe Middle East & Africa
Argentina | Español
Australia | English
Austria | Deutsch
Bangladesh | English
Belgium | Français
Belgium | Nederlands
Brazil | Português
Bulgaria | Български
Canada | English
Canada | Français
Central America | Español
Colombia | Español
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Egypt | English
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hong Kong S.A.R. | 繁體中文
Hungary | Magyar
India | English
Indonesia | English
Ireland | English
Israel | עברית
Italy | Italiano
Japan | 日本語
Korea | 한국어
Latvia | Latvian
Lithuania | Lithuanian
Mainland China | 中文
Malaysia | English
Mexico | Español
Netherlands | Nederlands
Norway | Norsk
Global | English
Novartis Foundation | English
Pakistan | English
Philippines | English
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Saudi Arabia | العربية
Serbia | Srpski
Singapore | English
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
South Africa | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Taiwan | 繁體中文
Thailand | ภาษาไทย
Türkiye | Türkçe
United Kingdom | English
United States | English
    • About 
      • Board of Directors 
        • Giovanni Caforio 
        • Simon Moroney 
        • Ton Buechner 
        • Patrice Bula 
        • Elizabeth (Liz) Doherty 
        • Ana de Pro Gonzalo 
        • Bridgette Heller 
        • Daniel Hochstrasser 
        • Frans van Houten 
        • Elizabeth McNally 
        • John D. Young 
        • Charlotte Pamer-Wieser 
      • Executive Committee 
        • Vasant (Vas) Narasimhan 
        • Shreeram Aradhye 
        • Victor Bulto 
        • Aharon (Ronny) Gal 
        • Karen L. Hale 
        • Patrick Horber 
        • Harry Kirsch 
        • Rob Kowalski 
        • Steffen Lang 
        • Fiona Marshall 
        • Lutz Hegemann 
        • Kees Roks 
        • Michelle Weese 
      • Products 
      • Therapeutic areas 
        • Cardiovascular, renal and metabolic 
        • Immunology 
        • Neuroscience 
        • Oncology 
      • People and culture 
      • Inclusion 
        • Promoting inclusion 
        • Building belonging 
        • Parental leave 
      • Novartis Gene Therapies 
      • Manufacturing 
      • Quality 
        • Audit program 
        • Novartis quality management system (QMS) 
        • Product and patient safety training 
        • Regulatory inspections 
        • Product recalls 
        • Third-party suppliers 
      • Awards and recognition 
      Mother and daughter cuddling on a bed in a kids room

      About

      Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.

    • Patients and caregivers 
      • Novartis commitment to patients and caregivers 
      • Diseases 
      • Patient organization funding 
      • Patients perspectives stories 
      Adult daughter talking to her senior parents on a bench in a park

      Patients and caregivers

      Information for patients and their caregivers including clinical trial recruiting, managed access programs, funding opportunities for patient organizations and side effects reporting.

    • Healthcare professionals 
      • Medical congresses and events 
        • ASCO Annual Meeting 
      • Products 
      • Novartis pipeline 
      • Managed access programs 
        • Zolgensma® Global Managed Access Program (gMAP) 
      • Novartis external funding 
      • Healthcare professional resources by country 
      • Investigator-initiated trials / studies 
      • Novartis medical information 
        • Submit medical enquiry 
      Doctor discussing illness with patient in an office

      Healthcare professionals

      Resources for physicians and other healthcare professionals including clinical trial recruiting, grant funding, congresses and country-level information.

    • Research and development 
      • Technology platforms 
      • Research disease areas 
        • Cardiovascular and metabolic disease research at Novartis 
        • DAx: exploratory disease research at Novartis 
        • Global Health disease area research at Novartis 
        • Immunology disease research at Novartis 
        • Neuroscience research at Novartis 
        • Oncology research at Novartis 
      • Novartis pipeline 
      • Research collaborations 
      • Collaborations 
      A female research scientist in a lab looking at a sample

      Research & development

      Discover how Novartis turns breakthrough science into transformative, high-value treatments.
       

    • ESG 
      • Access 
        • Creating sustainable business models 
        • Value-based pricing 
        • Sub-Saharan Africa 
        • Donations 
        • Novartis access principles 
        • Novartis oncology access 
        • Patents and licensing 
      • Environmental sustainability 
        • Climate 
        • Nature - Waste 
        • Nature - Water 
      • Ethics, risk and compliance 
        • Ethical behavior 
        • Compliance 
        • Human rights 
        • Learning and engagement 
        • Integrated risk assurance 
      • Global health 
        • Pandemic preparedness 
        • Avoidable blindness 
        • Chagas disease 
        • Leprosy 
        • Malaria 
        • Sickle cell disease (SCD) 
        • Novartis Foundation 
      • Inclusion 
      • ESG index 
      • Reporting and transparency hub 
        • ESG rating performance 
        • Targets 
        • Patient organization funding 
        • Payments to healthcare professionals 
        • Public policy 
        • A living wage 
        • A safe workplace 
        • Animal research 
      Family and friends having a party at home

      Environmental, social and governance

      Learn about our commitments to making a positive impact on the world by providing access to innovative medicines, protecting the environment, and upholding high ethical standards. Explore the Novartis in Society Integrated Report.

    • Investors 
      • Event calendar 
      • Financial data 
        • Novartis annual results 
        • Novartis quarterly results 
        • Novartis SEC filings 
        • Product sales 
        • Fixed-income securities 
        • Expected currency impact 
      • Share data and analysis 
        • Share monitor 
        • Dividend information 
        • Share ownership 
        • Share overview 
        • Return on investment calculator 
      • Shareholder information 
        • General Meetings 
        • American Depositary Receipts (ADR) 
        • Share buyback 
        • Frequently asked questions 
      • Company overview 
        • Corporate governance 
      • Reporting and transparency hub 
        • Reporting archive 
        • ESG rating performance 
        • Publications order form 
      • ESG 
      Business woman working on her laptop in a bright atmosphere

      Investors

      Updates and resources for investors including financial information, disclosures, events, share price, ESG and reporting.

    • News 
      • News archive  
      • Media library  
      • Stories 
      • Subscribe 
      • Events 
      Overhead view of a meeting room with people in the foreground and screens in the background

      News

      Information for journalists including media releases, statements, stories, multimedia resources and more.

    • Careers 
      • Career search 
      • Our business functions 
        • Careers in research and development 
        • Careers in operations 
        • Careers in commercial and sales 
        • Careers in global functions 
      • Why Novartis 
      • Career hub 
        • Temporary contracts 
      • Early careers 
        • Graduates 
        • Students 
        • US Biomedical Research internship programs 
        • Community exploration and learning lab (CELL) 
      Two business people

      Careers

      Novartis is hiring! Find open positions, learn more about our strategy and culture, and apply today.

    • Clinical trials 
    • Partnering 
    • Supplier portal 
    • Report side effects 
    • Contacts 
    Grandmother, mother and daughter smiling and laughing on a beach

    Home

    Working together, we can reimagine medicine to improve and extend people’s lives.

Stories

Story Navigation
  • All Topics
  • Discovery
  • From Our Labs
  • Patient Perspectives
  • Access to Healthcare
  • People & Culture
icon
  • Novartis cancer researchers advance precision medicine
    Discovery
    Novartis Institutes for BioMedical ResearchReimagine MedicineNext Generation SequencingTargeted TherapyClinical TrialsCancer Research Institute
    Jul 16, 2021

    Novartis cancer researchers advance precision medicine

    Learn how NIBR uses next generation sequencing to transform clinical trials and diagnostics in oncology.

    Discovery
  • Turning research advances into innovative medicines
    Discovery
    Novartis Institutes for BioMedical ResearchMusculoskeletal DiseasesCareers
    Jul 19, 2021

    Turning research advances into innovative medicines

    A strong background in biological research prepared Daniel Rooks for his role in shaping the early clinical development of new medicines

    Discovery
  • Rewriting the playbook for clinical testing in a rare disease
    Discovery
    Novartis Institutes for BioMedical ResearchRare DiseasesClinical TrialsGenetic Disease
    Jul 19, 2021

    Rewriting the playbook for clinical testing in a rare disease

    A Novartis team blazes new trails with an experimental treatment for spinal muscular atrophy.

    Discovery
  • Umbilical cords yield
    Discovery
    CancerCell and Gene TherapyInnovationMedical Innovations
    Jul 14, 2021

    Could umbilical cords yield more stem cells for life-saving transplants?

    Umbilical cords are a potentially life-saving source of blood stem cells for people with leukemia and other diseases. But there aren’t enough cells to meet demand. Now an experimental treatment offers hope for a solution.

    Discovery
  • How a love of sport led to a scientific breakthrough
    Discovery
    Drug DiscoveryFuture of HealthcareInnovation
    Jul 14, 2021

    How a love of sport led to a scientific breakthrough

    Jeff Weers’ passion inspired a new way of getting inhaled medicine past the body’s natural defenses to reach the lungs.

    Discovery
  • New recruit has big dreams for cancer immunotherapy
    Discovery
    Novartis Institutes for BioMedical ResearchReimagine MedicineTargeted Therapy
    Jul 16, 2021

    New recruit has big dreams for cancer immunotherapy

    Immunotherapy for cancer is on the brink of breakthroughs. Learn how NIBR have high expectations for this medical science.

    Discovery
  • Let there be sight
    Discovery
    Biomedical ResearchNovartis Institutes for BioMedical ResearchNew Scientific DiscoveriesEye Disorders
    Jul 15, 2021

    Let there be sight

    Discovery
  • Researchers aim to beat trick play by tumors with drug combo
    Discovery
    Biomedical ResearchDrug DiscoveryNovartis Institutes for BioMedical ResearchClinical ScienceCancer Research Institute
    Jul 19, 2021

    Researchers aim to beat trick play by tumors with drug combo

    Discovery
  • Trabecular meshwork cells
    Discovery
    Eye CareFuture of HealthcareInnovationMedical Innovations
    Jul 14, 2021

    A fresh look at fighting glaucoma

    Ask Alan Frohman how he found out that he had glaucoma, and he'll quickly tell you that there were no warning signs.

    Discovery
  • Hair cells
    Discovery
    Drug DiscoveryFuture of HealthcareInnovationLiving With DiseaseNovartis Institutes for BioMedical Research
    Jul 12, 2021

    Can we unlock the body's ability to regenerate lost hearing?

    When a middle-aged firefighter and active Boy Scout leader in the Midwestern United States lost his hearing a few years ago, he also faced the loss of his livelihood.

    Discovery
  • Biological battle of the bulge
    Discovery
    Future of HealthcareInnovation
    Jul 12, 2021

    Biological battle of the bulge

    John Hadcock’s wife Laura gave him an ultimatum: Run the energy out of Sunny, the new puppy, or take her back to the breeder. So Hadcock started running. On his first trip out, he had to stop half a mile in.

    Discovery
  • Novartis researches SMA’s genetic roots
    Discovery
    Novartis Institutes for BioMedical ResearchRare DiseasesClinical ResearchCareersBiomedical JobsGene TestingGenetic Disease
    Jul 16, 2021

    Novartis researches SMA’s genetic roots

    Spinal muscular atrophy (SMA) is the most common genetic casue of infant and toddler death. NIBR scientists are trying to make a back up gene take up the slack.

    Discovery

Pagination

  • ‹ Previous page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • › Next page

Novartis

Working together
  • Patients and caregivers
  • Healthcare professionals
  • Researchers
  • Job seekers
  • Journalists
  • Investors
Topics
  • Eurovision
  • Access
  • ESG
  • SpeakUp
Explore
  • Pipeline
  • Products
  • Clinical trials
  • Partnering
  • Events
Therapeutic areas
  • Cardiovascular, renal and metabolic
  • Immunology
  • Neuroscience
  • Oncology
Footer Bottom
© 2025 Novartis AG
  • Terms of use
  • Privacy
  • Cookie settings
  • Contacts
  • Locations
  • Site map
  • Open source
  • Web accessibility
Novartis Site Directory
This site is intended for a global audience